Anti-Human TIGIT (Tiragolumab) – Fc Muted™ (T765-500ug)

TIGIT (WUCAM) is an immunoreceptor that inhibits multiple immune cell responses, including T cell priming by dendritic cells, tumor cell killing by NK cells and cytotoxic T cells, and also enhances the immune suppressive activity of regulatory T cells1. TIGIT is a novel member of the Ig-superfamily distantly related to Nectins and Necls that aligns with the distal Ig-V-type domains of Nectin1-4, poliovirus receptor (PVR; CD155), DNAM-1 (CD226), and TACTILE (CD96)2. TIGIT is preferentially expressed on human B helper follicular T cells and binds with high affinity to PVR under both static and flow conditions. Additionally, TIGIT, DNAM-1, and TACTILE are expressed together on T cells and NK cells and share PVR as a ligand1. TIGIT is not detectable on the surface of resting peripheral blood mononuclear cells from healthy donors unless activated2. Tiragolumab is an investigational, fully human monoclonal antibody designed to prevent TIGIT interaction with its principal ligand CD155 (PVR; poliovirus receptor)3. Its immunotherapeutic effects are being evaluated as a single agent and in combination with the anti-PD-L1 antibody atezolizumab4.